Tivantinib: Phase III data

Top-line data from the double-blind, Asian Phase III ATTENTION trial in 307 EGFR wild-type patients with locally advanced or metastatic, non-squamous NSCLC who received 1-2 prior systemic cancer therapies showed that twice-daily tivantinib plus once-daily Tarceva erlotinib led to a median OS, the primary endpoint, of 12.9 months vs. 11.2 months for Tarceva alone (p=0.4). ArQule and partner Kyowa discontinued ATTENTION in 2012 after an imbalance of interstitial lung disease was observed between treatment arms (see BioCentury, Nov. 5, 2012). ...